Literature DB >> 28512998

Implementation of Treat-to-Target in Rheumatoid Arthritis Through a Learning Collaborative: Results of a Randomized Controlled Trial.

Daniel H Solomon1, Elena Losina1, Bing Lu1, Agnes Zak1, Cassandra Corrigan1, Sara B Lee1, Jenifer Agosti2, Asaf Bitton3, Leslie R Harrold4, Theodore Pincus5, Helga Radner6, Zhi Yu1, Josef S Smolen6, Liana Fraenkel7, Jeffrey N Katz1.   

Abstract

OBJECTIVE: Treat-to-target (TTT) is an accepted paradigm for the management of rheumatoid arthritis (RA), but some evidence suggests poor adherence. The purpose of this study was to test the effects of a group-based multisite improvement learning collaborative on adherence to TTT.
METHODS: We conducted a cluster-randomized quality-improvement trial with waitlist control across 11 rheumatology sites in the US. The intervention entailed a 9-month group-based learning collaborative that incorporated rapid-cycle improvement methods. A composite TTT implementation score was calculated as the percentage of 4 required items documented in the visit notes for each patient at 2 time points, as evaluated by trained staff. The mean change in the implementation score for TTT across all patients for the intervention sites was compared with that for the control sites after accounting for intracluster correlation using linear mixed models.
RESULTS: Five sites with a total of 23 participating rheumatology providers were randomized to intervention and 6 sites with 23 participating rheumatology providers were randomized to the waitlist control. The intervention included 320 patients, and the control included 321 patients. At baseline, the mean TTT implementation score was 11% in both arms; after the 9-month intervention, the mean TTT implementation score was 57% in the intervention group and 25% in the control group (change in score of 46% for intervention and 14% for control; P = 0.004). We did not observe excessive use of resources or excessive occurrence of adverse events in the intervention arm.
CONCLUSION: A learning collaborative resulted in substantial improvements in adherence to TTT for the management of RA. This study supports the use of an educational collaborative to improve quality.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28512998      PMCID: PMC5489379          DOI: 10.1002/art.40111

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  26 in total

Review 1.  The importance of the normality assumption in large public health data sets.

Authors:  Thomas Lumley; Paula Diehr; Scott Emerson; Lu Chen
Journal:  Annu Rev Public Health       Date:  2001-10-25       Impact factor: 21.981

2.  Implementation of treat-to-target in rheumatoid arthritis through a Learning Collaborative: Rationale and design of the TRACTION trial.

Authors:  Daniel H Solomon; Sara B Lee; Agnes Zak; Cassandra Corrigan; Jenifer Agosti; Asaf Bitton; Leslie Harrold; Elena Losina; Bing Lu; Ted Pincus; Helga Radner; Josef Smolen; Jeffrey N Katz; Liana Fraenkel
Journal:  Semin Arthritis Rheum       Date:  2016-03-08       Impact factor: 5.532

Review 3.  Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.

Authors:  Jaclyn Anderson; Liron Caplan; Jinoos Yazdany; Mark L Robbins; Tuhina Neogi; Kaleb Michaud; Kenneth G Saag; James R O'Dell; Salahuddin Kazi
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-05       Impact factor: 4.794

4.  A meta-analysis of interventions to improve care for chronic illnesses.

Authors:  Alexander C Tsai; Sally C Morton; Carol M Mangione; Emmett B Keeler
Journal:  Am J Manag Care       Date:  2005-08       Impact factor: 2.229

5.  Measuring the effectiveness of a collaborative for quality improvement in pediatric asthma care: does implementing the chronic care model improve processes and outcomes of care?

Authors:  Rita Mangione-Smith; Matthias Schonlau; Kitty S Chan; Joan Keesey; Mayde Rosen; Thomas A Louis; Emmett Keeler
Journal:  Ambul Pediatr       Date:  2005 Mar-Apr

6.  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis.

Authors:  Timo Möttönen; Pekka Hannonen; Markku Korpela; Martti Nissilä; Hannu Kautiainen; Jorma Ilonen; Leena Laasonen; Oili Kaipiainen-Seppänen; Per Franzen; Tapani Helve; Juhani Koski; Marianne Gripenberg-Gahmberg; Riitta Myllykangas-Luosujärvi; Marjatta Leirisalo-Repo
Journal:  Arthritis Rheum       Date:  2002-04

7.  Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial.

Authors:  L H D van Tuyl; W F Lems; A E Voskuyl; P J S M Kerstens; P Garnero; B A C Dijkmans; M Boers
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103

8.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.

Authors:  Catriona Grigor; Hilary Capell; Anne Stirling; Alex D McMahon; Peter Lock; Ramsay Vallance; Wilma Kincaid; Duncan Porter
Journal:  Lancet       Date:  2004 Jul 17-23       Impact factor: 79.321

9.  Effects of a quality improvement collaborative on the outcome of care of patients with HIV infection: the EQHIV study.

Authors:  Bruce E Landon; Ira B Wilson; Keith McInnes; Mary Beth Landrum; Lisa Hirschhorn; Peter V Marsden; David Gustafson; Paul D Cleary
Journal:  Ann Intern Med       Date:  2004-06-01       Impact factor: 25.391

Review 10.  Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.

Authors:  Monika Schoels; Rachel Knevel; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios T Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maxime Dougados; Paul Emery; Desirée van der Heijde; Tom W J Huizinga; Joachim Kalden; Edward C Keystone; Tore K Kvien; Emilio Martin-Mola; Carlomaurizio Montecucco; Maarten de Wit; Josef S Smolen
Journal:  Ann Rheum Dis       Date:  2010-04       Impact factor: 19.103

View more
  16 in total

1.  Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial.

Authors:  Daniel H Solomon; Bing Lu; Zhi Yu; Cassandra Corrigan; Leslie R Harrold; Josef S Smolen; Liana Fraenkel; Jeffrey N Katz; Elena Losina
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-10       Impact factor: 4.794

2.  Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease.

Authors:  Yomei Shaw; Chung-Chou H Chang; Marc C Levesque; Julie M Donohue; Kaleb Michaud; Mark S Roberts
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-04-16       Impact factor: 4.794

3.  Implementation of Treat-to-Target for Rheumatoid Arthritis in the US: Analysis of Baseline Data From a Randomized Controlled Trial.

Authors:  Zhi Yu; Bing Lu; Jenifer Agosti; Asaf Bitton; Cassandra Corrigan; Liana Fraenkel; Leslie R Harrold; Elena Losina; Jeffrey N Katz; Daniel H Solomon
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-04-12       Impact factor: 4.794

4.  Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial.

Authors:  Agnes Zak; Cassandra Corrigan; Zhi Yu; Asaf Bitton; Liana Fraenkel; Leslie Harrold; Josef S Smolen; Daniel H Solomon
Journal:  Rheumatology (Oxford)       Date:  2018-11-01       Impact factor: 7.580

5.  Implementation of the treat-to-target approach and treatment satisfaction in patients with rheumatoid arthritis: perspectives of Chinese rheumatologists.

Authors:  Jiu Liang Zhao; Xin Liu; Jin Nan Li; Meng Ru Liu; Elke Rottier; Yan Zhao; Xiao Feng Zeng
Journal:  Clin Rheumatol       Date:  2022-05-17       Impact factor: 3.650

6.  Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.

Authors:  Daniel H Solomon; Zhi Yu; Jeffrey N Katz; Asaf Bitton; Cassandra Corrigan; Liana Fraenkel; Leslie R Harrold; Josef S Smolen; Elena Losina; Bing Lu
Journal:  Arthritis Care Res (Hoboken)       Date:  2019-07-19       Impact factor: 4.794

7.  Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry.

Authors:  Dimitrios A Pappas; Robert A Gerber; Heather J Litman; David Gruben; Jamie Geier; Winnie D Hua; Connie Chen; Youfu Li; Joel M Kremer; John S Andrews; Jeffrey A Bourret
Journal:  Am Health Drug Benefits       Date:  2018-05

8.  Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Authors:  Josef S Smolen; Monika Schöls; Jürgen Braun; Maxime Dougados; Oliver FitzGerald; Dafna D Gladman; Arthur Kavanaugh; Robert Landewé; Philip Mease; Joachim Sieper; Tanja Stamm; Maarten de Wit; Daniel Aletaha; Xenofon Baraliakos; Neil Betteridge; Filip van den Bosch; Laura C Coates; Paul Emery; Lianne S Gensler; Laure Gossec; Philip Helliwell; Merryn Jongkees; Tore K Kvien; Robert D Inman; Iain B McInnes; Mara Maccarone; Pedro M Machado; Anna Molto; Alexis Ogdie; Denis Poddubnyy; Christopher Ritchlin; Martin Rudwaleit; Adrian Tanew; Bing Thio; Douglas Veale; Kurt de Vlam; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2017-07-06       Impact factor: 19.103

9.  Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.

Authors:  Glenn Haugeberg; Brigitte Michelsen; Stig Tengesdal; Inger Johanne Widding Hansen; Andreas Diamantopoulos; Arthur Kavanaugh
Journal:  Arthritis Res Ther       Date:  2018-08-02       Impact factor: 5.156

Review 10.  Physician Adherence to Treat-to-Target and Practice Guidelines in Rheumatoid Arthritis.

Authors:  Bogdan Batko; Krzysztof Batko; Marcin Krzanowski; Zbigniew Żuber
Journal:  J Clin Med       Date:  2019-09-08       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.